<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92324</article-id><article-id pub-id-type="doi">10.7554/eLife.92324</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92324.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>The molecular basis of Abelson kinase regulation by its αI-helix</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-333889"><name><surname>Paladini</surname><given-names>Johannes</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7920-2219</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-333890"><name><surname>Maier</surname><given-names>Annalena</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-89026"><name><surname>Habazettl</surname><given-names>Judith Maria</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7976-768X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-333891"><name><surname>Hertel</surname><given-names>Ines</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-333892"><name><surname>Sonti</surname><given-names>Rajesh</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa2">§</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-89028"><name><surname>Grzesiek</surname><given-names>Stephan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1998-4225</contrib-id><email>stephan.grzesiek@unibas.ch</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02s6k3f65</institution-id><institution>Structural Biology and Biophysics, Biozentrum, University of Basel</institution></institution-wrap><addr-line><named-content content-type="city">Basel</named-content></addr-line><country>Switzerland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Tissue Engineering + Biofabrication Laboratory, Department of Health Sciences &amp; Technology, ETH Zurich, Zurich, Switzerland</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>04</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP92324</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-09-06"><day>06</day><month>09</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-10-06"><day>06</day><month>10</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.04.560671"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-01"><day>01</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92324.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-02-05"><day>05</day><month>02</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92324.2"/></event></pub-history><permissions><copyright-statement>© 2023, Paladini, Maier et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Paladini, Maier et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92324-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-92324-figures-v1.pdf"/><abstract><p>Abelson tyrosine kinase (Abl) is regulated by the arrangement of its regulatory core, consisting sequentially of the SH3, SH2, and kinase (KD) domains, where an assembled or disassembled core corresponds to low or high kinase activity, respectively. It was recently established that binding of type II ATP site inhibitors, such as imatinib, generates a force from the KD N-lobe onto the SH3 domain and in consequence disassembles the core. Here, we demonstrate that the C-terminal αI-helix exerts an additional force toward the SH2 domain, which correlates both with kinase activity and type II inhibitor-induced disassembly. The αI-helix mutation E528K, which is responsible for the ABL1 malformation syndrome, strongly activates Abl by breaking a salt bridge with the KD C-lobe and thereby increasing the force onto the SH2 domain. In contrast, the allosteric inhibitor asciminib strongly reduces Abl’s activity by fixating the αI-helix and reducing the force onto the SH2 domain. These observations are explained by a simple mechanical model of Abl activation involving forces from the KD N-lobe and the αI-helix onto the KD/SH2SH3 interface.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Abelson tyrosine kinase</kwd><kwd>chronic myelogenous leukemia</kwd><kwd>allosteric activation</kwd><kwd>αI-helix</kwd><kwd>asciminib</kwd><kwd>NMR</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>E. coli</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>31-149927</award-id><principal-award-recipient><name><surname>Grzesiek</surname><given-names>Stephan</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>31-173089</award-id><principal-award-recipient><name><surname>Grzesiek</surname><given-names>Stephan</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>31-201270</award-id><principal-award-recipient><name><surname>Grzesiek</surname><given-names>Stephan</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004361</institution-id><institution>Krebsliga Schweiz</institution></institution-wrap></funding-source><award-id>KFS-3603-022015</award-id><principal-award-recipient><name><surname>Grzesiek</surname><given-names>Stephan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>High-resolution NMR data and precise kinase activity assays on Abelson kinase bearing mutations in its αI-helix identify the αI-helix parts involved in disassembly of Abelson’s regulatory core and kinase activation.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Abelson tyrosine kinase (Abl) is crucial for many cellular processes including proliferation, division, survival, DNA repair and migration (<xref ref-type="bibr" rid="bib27">Van Etten, 1999</xref>; <xref ref-type="bibr" rid="bib21">Pendergast, 2002</xref>). Under non-pathological conditions, Abl is tightly regulated with very low intrinsic activity in unstimulated cells (<xref ref-type="bibr" rid="bib10">Hantschel, 2012</xref>). However, the oncogenic t(9;22)(q34;q11) chromosome translocation (Philadelphia chromosome) leads to the expression of the highly active fusion protein Bcr-Abl and subsequently to chronic myeloid leukemia (CML; <xref ref-type="bibr" rid="bib23">Rowley, 1973</xref>; <xref ref-type="bibr" rid="bib5">Deininger et al., 2000</xref>; <xref ref-type="bibr" rid="bib3">Braun et al., 2020</xref>). The orthosteric ATP site inhibitors imatinib (Gleevec), nilotinib (Tasigna), and dasatinib (Sprycel) constitute the front-line therapy against CML (<xref ref-type="bibr" rid="bib11">Hantschel et al., 2012</xref>; <xref ref-type="bibr" rid="bib20">O’Hare et al., 2009</xref>; <xref ref-type="bibr" rid="bib24">Shah et al., 2007</xref>), but the emergence of drug-resistant point mutations in a fraction of patients has created the need for alternatives (<xref ref-type="bibr" rid="bib11">Hantschel et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Eide et al., 2019</xref>). In particular, the recently FDA-approved allosteric inhibitor asciminib (ABL001; <xref ref-type="bibr" rid="bib29">Wylie et al., 2017</xref>), which targets the myristoyl binding pocket (STAMP, specifically targeting the ABL myristoyl pocket), shows high promise to overcome these resistances (<xref ref-type="bibr" rid="bib22">Réa et al., 2021</xref>). This development now enables dual Bcr-Abl targeting and thereby therapy of patients bearing compound mutations (<xref ref-type="bibr" rid="bib29">Wylie et al., 2017</xref>; <xref ref-type="bibr" rid="bib7">Eide et al., 2019</xref>). However, the exact molecular mechanism of the interplay between allosteric and orthosteric inhibition is currently still unclear.</p><p>Under healthy conditions, Abl regulation is achieved by a set of interactions within its regulatory core, consisting sequentially of the SH3, SH2 and kinase (KD) domains, and the preceding ~60–80-residue-long N-terminal tail (N-cap) (<xref ref-type="bibr" rid="bib18">Nagar et al., 2003</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). The N-cap varies between splice variants 1a and 1b with Abl 1b being 19 residues longer and N-terminally myristoylated. Crystal structures of the autoinhibited Abl 1b core with the myristoylated N-cap (<xref ref-type="bibr" rid="bib18">Nagar et al., 2003</xref>; <xref ref-type="bibr" rid="bib9">Hantschel et al., 2003</xref>; <xref ref-type="bibr" rid="bib19">Nagar et al., 2006</xref>) reveal a tight, almost spherical assembly (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). This assembly appears stabilized by several interactions: (i) the docking of the SH3 domain to the proline-rich linker that connects SH2 domain and KD N-lobe; (ii) extensive contacts of SH3 domain and KD N-lobe as well as SH2 domain and KD C-lobe and (iii) the docking of the N-terminal myristoyl into a hydrophobic cleft at the bottom of the KD C-lobe. The assembly of the core impedes efficient substrate binding (<xref ref-type="bibr" rid="bib18">Nagar et al., 2003</xref>), presumably by hindering hinge motions between the KD C- and N-lobes (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>), and reduces the kinase activity by 10- to 100-fold relative to the isolated kinase domain (<xref ref-type="bibr" rid="bib10">Hantschel, 2012</xref>; <xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>). In contrast, the active state of Abl is thought to require the disassembly of the core to make the substrate binding site accessible and expose the protein-protein contact sites of the SH2 and SH3 domains.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Domain organization of Abl and ligand-induced conformations of the Abl core.</title><p>(<bold>A</bold>) Domain organization of Abl isoforms 1a,b and of the chronic myeloid leukemia (CML)-inducing fusion protein Bcr-Abl. (<bold>B</bold>) Crystal structure of the N-terminally myristoylated Abl 1b isoform (residues 2–531, PDB 2FO0). SH3 domain (green), SH2 domain (yellow), KD-SH2 linker (grey), kinase domain (KD) N- and C-lobes (KD-N and KD-C, respectively, blue), activation loop (A-loop, green), and αI-helix (cyan) are shown in cartoon representation. The myristoyl is shown as yellow spheres. The N-cap (aa 2–82), which is largely not observed in the crystal, is indicated as a dashed brown line. A schematic representation on the right indicates the position of the kink in the αI-αI’ helix. (<bold>C</bold>) Alignment of the crystal structure of a KD-only construct with unliganded myristoyl pocket (blue, PDB 1M52) with the assembled Abl core structure (PDB 2FO0). The SH3 and SH2 domains of the latter are displayed as in panel B. (<bold>D</bold>) Model of a single conformation of the dynamical imatinib-bound, disassembled Abl core as derived by NMR and SAXS (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>). The coloring follows panel B with the exception of the activation loop (magenta). Imatinib is shown as magenta sticks. Blue arrows indicate relative motions of the SH3, SH2, and KD domains.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92324-fig1-v1.tif"/></fig><p>The C-terminal αI-helix (residues 504–522, 1b numbering used throughout) adopts a straight conformation (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) in crystal structures of the isolated Abl kinase domain with an empty myristoyl binding pocket (PDB 1M52; <xref ref-type="bibr" rid="bib17">Nagar et al., 2002</xref>). In contrast, in the assembled core structures (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, PDB 2FO0; <xref ref-type="bibr" rid="bib19">Nagar et al., 2006</xref>), the helix breaks into two parts αI (residues 504–515) and αI’ (residues 520–531) connected by the αI–αI’ loop, with the αI’ part bending toward the myristoyl bound in the myristoyl pocket (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Notably, the straight αI-helix of the isolated Abl kinase domain would clash with the SH2 domain in the assembled core (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). This has led to the notion that myristoyl binding induces a bend of the αI-helix, thereby stabilizing the assembled core and reducing activity (<xref ref-type="bibr" rid="bib9">Hantschel et al., 2003</xref>; <xref ref-type="bibr" rid="bib18">Nagar et al., 2003</xref>). Following this idea, allosteric inhibitors have been developed that target the myristoyl pocket (<xref ref-type="bibr" rid="bib1">Adrián et al., 2006</xref>; <xref ref-type="bibr" rid="bib13">Jahnke et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Zhang et al., 2010</xref>), leading to the drug asciminib (<xref ref-type="bibr" rid="bib29">Wylie et al., 2017</xref>). Importantly, not all myristoyl pocket binders act as allosteric inhibitors, but only those that also bend the αI-helix (<xref ref-type="bibr" rid="bib13">Jahnke et al., 2010</xref>). The importance of this structural region for Abl’s function is highlighted by several mutations in the αI’-helix, including E528K at its C-terminal end associated with the recently described ABL1 malformation syndrome leading to congenital heart disease, skeletal malformations, characteristic facies, and hearing impairment (<xref ref-type="bibr" rid="bib28">Wang et al., 2017</xref>; <xref ref-type="bibr" rid="bib2">Blakes et al., 2021</xref>). The disruption of interactions by these mutations has been hypothesized as the cause for a concomitant increase in kinase activity (<xref ref-type="bibr" rid="bib2">Blakes et al., 2021</xref>).</p><p>Several observations indicate that the described role of the αI-helix in the destabilization of the regulatory core is incomplete. First, the αI-helix is rather flexible in solution (<xref ref-type="bibr" rid="bib13">Jahnke et al., 2010</xref>; <xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>) and may avoid the steric clash with the SH2 domain in the assembled conformation. Indeed, an Abl<sup>83-534</sup> construct comprising only the SH3-SH2-KD domains but not the myristoylated N-cap adopts an assembled conformation in solution (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>) and has strongly reduced enzymatic activity relative to the isolated KD (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>). Second, high-affinity binding of type II ATP site inhibitors to the ATP site (<xref ref-type="bibr" rid="bib8">Grzesiek et al., 2022</xref>; <xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>), which induce an inactive activation loop (A-loop) conformation in the KD, disassembles the core into an arrangement where SH3 and SH2 domains move with high-amplitude nanosecond motions relative to the KD (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>; <xref ref-type="fig" rid="fig1">Figure 1D</xref>). This type II inhibitor-disassembled core is reassembled when allosteric inhibitors bind to the myristate pocket (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>), indicating a cross talk between ATP site and the αI-helix/myristate pocket. The inhibitor-induced disassembly correlates with a slight rotation of the KD N-lobe toward the SH3 domain caused by the push of type II inhibitors onto the A-loop and subsequently the P-loop (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>). To explain these observations, we have proposed a mechanical model where both the rotation of the KD N-lobe and the flexible αI-helix exert destabilizing forces onto the SH3/SH2-KD interface, which together lead to the disassembly of the core (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>).</p><p>Here, we prove and refine this model of allosteric activation and interaction between the αI-helix and the ATP site by stepwise shortening the Abl KD C-terminus from residue 534 to residue 513. We show that αI-helix truncations beyond residue 519, namely removal of the αI–αI’ loop reduce both the imatinib-induced disassembly of the Abl regulatory core and its kinase activity, which confirms the cross talk between αI/SH2 and KD N-lobe/SH3 interfaces. A salt bridge between E528 in the αI’-helix and R479 on the KD C-lobe appears as a crucial element of Abl core regulation. Its disruption by the malignant mutation E528K results in a strongly increased kinase activity due to the unlocking of the αI’-helix. A simple mechanical model of Abl regulation involving the two forces from the KD N-lobe and the αI’-helix onto the KD/SH3SH2 interface explains all current observations.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><sec id="s2-1"><title>Expression of C-terminal Abl truncation constructs</title><p>To test the impact of the C-terminal αI-helix on Abl’s conformational equilibria and activity, Abl constructs of the regulatory core (Abl<sup>83-534</sup>) were expressed with decreasing αI-helix length by introducing stop codons (<xref ref-type="fig" rid="fig2">Figure 2</xref>). While Abl constructs with partial truncations of the αI’-helix (Abl<sup>83-522</sup> and Abl<sup>83-525</sup>) could not be purified to homogeneity and were very unstable, the first well purifiable truncation construct was Abl<sup>83-519</sup>, which misses the entire αI’-helix part of the myristoyl-bound conformation (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). As compared to Abl<sup>83-534</sup>, its expression yield is reduced about fourfold as quantified by western blot (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) and analysis of the fully purified construct (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). The C-terminus was then further truncated by one amino acid at a time until Abl<sup>83-513</sup>, thereby removing sequentially the αI–αI’ loop and the last two residues T514 and M515 of the αI-helix part of the myristoyl-bound conformation. The resulting constructs had further reduced expression yields down to less than 10% for the least expressing Abl<sup>83-513</sup> relative to Abl<sup>83-534</sup> (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). This reduction in yield can be rationalized by the sequential loss of stabilizing interactions between the αI-αI’ loop and the αI’-helix involving residues F516, Q517, S520, and D523 (<xref ref-type="bibr" rid="bib18">Nagar et al., 2003</xref>; <xref ref-type="bibr" rid="bib19">Nagar et al., 2006</xref>) and the loss of α-helical backbone hydrogen bonds originating at T514 and M515.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Production of C-terminally truncated Abl regulatory core constructs.</title><p>(<bold>A</bold>) Detailed view of the interaction site between the SH2 domain (yellow) and the C-terminus of the Abl KD with its αH- (dark blue) and αI- (cyan) helices from the crystal structure of the assembled Abl core (PDB 2FO0). The C<sup>α</sup>-atoms of M515, Q517, and S519 are shown as cyan spheres (<bold>B</bold>) Top: western blot of <italic>E. coli</italic>-expressed, soluble truncated Abl constructs in the supernatant after cell lysis. Bottom: expression yields of the corresponding Abl constructs as quantified from the gel bands. The numbers on the horizontal axis denote the last amino acid of the respective construct Abl<sup>83-X</sup>. (<bold>C</bold>) Relative yields of the purified truncated Abl constructs and Abl<sup>83-534,E528K</sup> as quantified by OD<sub>280</sub>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Uncropped original image file of western blot in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92324-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Uncropped western blot of <xref ref-type="fig" rid="fig2">Figure 2B</xref> with annotation of relevant bands.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92324-fig2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92324-fig2-v1.tif"/></fig><p>Due to these severe reductions in yield, large-scale expressions of <sup>15</sup>N-labeled constructs for NMR and kinase assays were then only carried out for Abl<sup>83-519</sup>, Abl<sup>83-517</sup>, and Abl<sup>83-515</sup>. The final yield after purification for Abl<sup>83-515</sup> was 0.16 mg per liter expression culture and reduced about 20-fold relative to Abl<sup>83-534</sup> (3.0 mg/L; <xref ref-type="fig" rid="fig2">Figure 2C</xref>). Furthermore, also a full-length Abl<sup>83-534</sup> construct harboring the malignant E528K mutation could be purified with good yield (1.3 mg/L).</p></sec><sec id="s2-2"><title>Truncation of the C-terminal αI–αI’-loop leads to less disassembly of the Abl core by imatinib</title><p>Assembled and disassembled Abl core conformations can be readily distinguished by the <sup>1</sup>H-<sup>15</sup>N chemical shifts of the SH3 and SH2 domain backbone resonances (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>; <xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>). The well-resolved resonances of V130, T136, and G149 shift particularly strongly (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, left) when the type II inhibitor imatinib binds to Abl<sup>83-534</sup>, which leads to the disassembly of the Abl core as shown by SAXS, NMR relaxation and RDC data (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>). No pronounced chemical shift changes are observed for these resonances between the Abl<sup>83-534</sup>•imatinib and the Abl<sup>83-‍519</sup>•imatinib complexes, indicating that the latter is also disassembled. Upon further truncation of the Abl C-terminus (Abl<sup>83-517</sup> and Abl<sup>83-515</sup>), the resonances of the imatinib complexes shift on a straight line from the disassembled Abl<sup>83-534</sup>•imatinib in the direction of the Abl<sup>83-534</sup> apo form, which is in the assembled conformation (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>). In contrast, the apo forms of the Abl C-terminal truncations have very similar, yet not completely identical, chemical shifts to apo Abl<sup>83-534</sup> (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, center) which indicates that they are also assembled (see below).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>NMR evidence for reduced imatinib-induced core disassembly in truncated Abl constructs.</title><p>(<bold>A</bold>) Selected <sup>1</sup>H-<sup>15</sup>N TROSY resonances that report on the imatinib-induced disassembly (left and middle panels) and the SH3SH2/KD interface (right panel). The label indicates the last amino acid of the respective Abl<sup>83-X</sup> construct. Abbreviations: ima:imatinib, PD16:PD166326.(<bold>B</bold>) Scores plot of the PCA of the SH3 and SH2 domain chemical shifts of various Abl core complexes and apo forms. Abbreviations: asci:asciminib, bosu:bosutinib, axi:axitinib, dasa:dasatinib, danu:danusertib, toza:tozasertib, staur:staurosporine, reba:rebastinib, pona:ponatinib, nilo:nilotinib, bafe:bafetinib. (<bold>C</bold>) Loadings plot of the PCA shown in panel B indicating contributions of individual <sup>1</sup>H<sup>N</sup> and <sup>15</sup>N chemical shifts to the first two PCs. Resonances with absolute PC1 or PC2 loadings larger than 0.15 are highlighted in red and blue, respectively. V92 has large loadings for both PCs and is shown in pink. (<bold>D</bold>) Residues with large PC1 or PC2 loadings according to panel C indicated as spheres within the assembled Abl core structure (PDB 2FO0). The color coding follows panel C.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92324-fig3-v1.tif"/></fig><p>A full quantitative analysis of the observed SH3 and SH2 <sup>1</sup>H-<sup>15</sup>N chemical shifts for all Abl constructs in apo form and in complex with imatinib by Principal Component Analysis (PCA) is shown <xref ref-type="fig" rid="fig3">Figure 3B and C</xref>. The PCA also includes previously observed chemical shifts for binary Abl<sup>83-534</sup> complexes with 5 type II, 8 type I ATP site inhibitors, AMP-PNP, as well as with the allosteric inhibitors GNF-5 and asciminib (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>). The PCA comprises 113 SH3-SH2 distinct <sup>1</sup>H-<sup>15</sup>N resonances (out of a total of 148 non-proline residues). The combined first (PC1) and second (PC2) principal components explain 77% of these data.</p><p>As observed previously (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>), the PC1 scores (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) readily distinguish between assembled and disassembled conformations. All type II inhibitor complexes cluster in one PC1 score region corresponding to disassembled conformations, whereas complexes with type I inhibitors, allosteric inhibitors, and AMP-PNP as well as the full-length apo form cluster in a second PC1 score region corresponding to assembled conformations. Notably, all truncated apo forms also fall in the latter PC1 score region, corroborating clearly that these are also in the assembled conformation. The assembled conformations are further differentiated by the PC2 scores into a region comprising all type I inhibitor complexes and a second region containing all apo forms that have no inhibitor in the ATP site, that is the allosteric inhibitor and AMP-PNP complexes.</p><p>The PCA loadings (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) show the contributions of individual residue chemical shift changes to PC1 and PC2. Residues with |PC1|≥0.15, which are strongly affected by the core assembly-disassembly transition, are annotated in red and indicated as red spheres in the assembled Abl core structure (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). While they are distributed to some extent across both SH3 and SH2 domains, residues G104, T136, Y89, and G149 form a notable cluster at the SH3/SH2 interface. This is consistent with the altered environment of residues in this region expected from the disassembly of the regulatory core and the increased interdomain flexibility (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>). Residues strongly contributing to PC2 (|PC2|≥0.15) are marked in blue in <xref ref-type="fig" rid="fig3">Figure 3C and D</xref>. Previously, the largest PC2 score differences of Abl<sup>83-534</sup> were observed between the Abl<sup>83-534</sup>•type I inhibitor complexes and apo Abl<sup>83-534</sup> (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>). Interestingly, now the truncated apo Abl constructs shift even further away from the type I inhibitor complexes than apo Abl<sup>83-534</sup>, but show little difference among their different truncation lengths. In contrast to PC1, residues contributing most to PC2 are located either in the upper part of the SH3 domain toward the KD N-lobe or the upper part of the SH2 domain toward the KD αI–αI’ loop (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Both regions are also in direct contact with the KD-SH2 linker (green, <xref ref-type="fig" rid="fig3">Figure 3D</xref>). As the affected residues react differently to perturbations by type I inhibitors and truncation of the αI’-helix (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, right), we attribute this behavior to two effects intermixed into the PC2 detection: (i) a minor rearrangement of the SH3/KD N-lobe interface caused by filling of the ATP pocket with type I inhibitors, which in contrast to the stronger N-lobe motion induced by type II inhibitors does not yet lead to core disassembly and (ii) a small rearrangement of the SH2/KD C-lobe interface caused by shortening and mutations of the αI-helix.</p></sec><sec id="s2-3"><title>Conformational changes within KD and SH2 domain induced by the αI-helix truncation</title><p>The PCA analysis shown in <xref ref-type="fig" rid="fig3">Figure 3</xref> was restricted to the SH3 and SH2 domains and did not include the KD, since the <sup>1</sup>H-<sup>15</sup>N resonances of the former are best suited to monitor the Abl regulatory core assembly-disassembly transition, while not being affected by local changes from ligand binding. An analogous PCA analysis of the <sup>1</sup>H-<sup>15</sup>N KD resonances (164 out of a total of 270 non-proline amino acids) for all investigated Abl constructs and complexes reveals details of these local ligand-induced structural changes as well as of the effects of the αI-helix truncations. Similar to the analysis of the SH2 and SH3 resonances, the PC1/PC2 scores plot of the KD resonances (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) clearly separates type I and type II ATP site inhibitor complexes, as well as all forms without any ATP site inhibitor. The respective PC1/PC2 loadings (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>) show that the amino acids, which cause this separation by their pronounced shifts, are distributed across the entire KD. However, effects from the ATP site, allosteric site binding, and the αI-helix truncation are strongly intermixed in this analysis, and specific causes are hard to distinguish.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>PCAs of resonances comprising the KD or entire Abl core.</title><p>(<bold>A</bold>) PCA scores of the KD resonances of all complexes shown in <xref ref-type="fig" rid="fig3">Figure 3B</xref>. (<bold>B</bold>) PCA scores of the KD resonances of only type I and type II inhibitor complexes. The respective loadings are shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>. (<bold>C</bold>) Residues with absolute PC1 loadings larger than 0.15 for the analysis in panel B are shown as red spheres in the assembled core structure (PDB 2FO0). The P-loop is shown in orange and the A-loop in its active (green, PDB 2FO0) as well as inactive (magenta, PDB 2HYY <xref ref-type="bibr" rid="bib4">Cowan-Jacob et al., 2007</xref>) conformation. (<bold>D</bold>) PCA scores of the resonances of the entire Abl core for the apo forms of all αI-helix variants. The respective loadings are shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>. (<bold>E</bold>) Residues with absolute PC1 loadings larger than 0.1 of the analysis in panel D are shown as red spheres in the assembled core structure (PDB 2FO0).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92324-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>PCA loadings showing the contributions of the <sup>1</sup>H and <sup>15</sup>N chemical shifts of individual residues to PC1 and PC2.</title><p>(<bold>A</bold>) PCA of all KD chemical shifts of all investigated complexes corresponding to <xref ref-type="fig" rid="fig4">Figure 4A</xref>. (<bold>B</bold>) PCA of KD chemical shifts for type I and type II inhibitor complexes (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). Residues with absolute PC1 values larger than 0.15 are indicated in red. (<bold>C</bold>) PCA of all SH3SH2KD shifts of all apo forms (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>). Residues with sizeable absolute PC1 values larger than 0.1 or sizeable PC2 (&lt; -0.1 or &gt; 0.125) are indicated in red and blue, respectively. V151, N316, and K438 have both sizeable PC1 and PC2 and is shown in magenta.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92324-fig4-figsupp1-v1.tif"/></fig></fig-group><p>To separate these effects, two additional PCAs were carried out. The first was restricted to the KD resonances of only type I and type II inhibitor-bound forms (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). The PC1 scores of this analysis separate the two types of inhibitors in a very clear manner (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The respective PC1 loadings (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>) show that the affected residues are mostly adjacent to the A-loop in its inactive conformation, which is observed in the type II inhibitor-bound crystal structures, as well as adjacent to the nearby P-loop. Thus, these residues evidently feel a force when type II inhibitors bind. This finding corroborates the previously proposed mechanism for type II inhibitor-induced core disassembly (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>), namely that type II inhibitors push onto the A-loop and subsequently the P-loop thereby rotating the KD N-lobe toward the SH3 domain and exerting a destabilizing force onto the SH3/KD N-lobe interface.</p><p>A further PCA was calculated on all observed SH3-SH2-KD resonances of all apo forms (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>). This analysis of the entire apo SH3-SH2-KD protein is meaningful, since the KD resonances are not dominated by the strong effects of ATP site binders. The PC1 scores (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) separate wild-type apo Abl<sup>83-534</sup> from all the truncated Abl apo forms (Abl<sup>83-515</sup>, Abl<sup>83-517</sup>, Abl<sup>83-519</sup>) and the Abl<sup>83-534,E528K</sup> mutant. The respective PC1 loadings of significant size (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> |PC1|&gt;0.1) are mostly from amino acids in the vicinity of the αI-helix and myristoyl pocket, indicating localized structural changes in this region due to the mutations of the αI-helix.</p></sec><sec id="s2-4"><title>The αI-helix contributes directly to Abl activation</title><p>The NMR data show that the αI-helix plays a crucial role in the imatinib-induced Abl core disassembly and exerts forces onto the SH2-SH3 to KD interface. To quantify the role of the αI-helix in the regulation of Abl, we assayed the kinase activity of the different truncation constructs in vitro using the optimized Abltide peptide substrate (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). Indeed, the stepwise truncation of the αI-helix continuously decreased the Michaelis-Menten v<sub>max</sub> (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>) for the different helix lengths reaching a minimum of 3.2 nmol P<sub>i</sub> min<sup>–1</sup>μmol<sup>–1</sup> for Abl<sup>83-515</sup>, which is about 30 times smaller than the wild-type Abl<sup>83-534</sup> value (89.4 nmol P<sub>i</sub> min<sup>–1</sup>μmol<sup>–1</sup>). In contrast, the substrate dissociation constant K<sub>M</sub> remained almost constant within the error limits (~40–90 μM). The reduction of the enzymatic activity by the αI truncations is consistent with the notion that a shorter αI-helix favors the assembled conformation of the Abl regulatory core, thereby hindering ‘breathing’ motions between the KD N- and C-lobes and impeding substrate binding. Conversely, the full-length αI-helix exerts forces onto the SH3-SH2 interface that either increase KD N-/KD C-lobes hinge motions or lead to complete core disassembly, thereby increasing the enzymatic activity.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>In vitro kinase activity assays and effect of the E528K mutation.</title><p>(<bold>A</bold>) Specific kinase activity of Abl<sup>83-534, E528K</sup> (orange), Abl<sup>83-534</sup> (red), Abl<sup>83-519</sup> (light blue), Abl<sup>83-517</sup> (green), Abl<sup>83-515</sup> (magenta), and Abl<sup>83-534</sup>•asciminib (asc, blue). Sample sizes and statistical information are given in <xref ref-type="table" rid="table1">Table 1</xref>. (<bold>B</bold>) Bar plot of fitted Michaelis-Menten v<sub>max</sub> values derived from the kinase assays in panel A. Numerical values are given in <xref ref-type="table" rid="table1">Table 1</xref>. (<bold>C</bold>) Detailed view of the E528-R479 salt bridge in the structure of the assembled Abl core (PDB 2FO0). Distances between the E528 carboxylate oxygens and the guanidinium sidechain hydrogen of R479 as well as the backbone amide hydrogen of E485 are displayed as dashed lines and indicated in Angstrom. (<bold>D</bold>) Superpositions of the <sup>1</sup>H-<sup>15</sup>N TROSY resonances of V130, T136, and G149 for apo Abl<sup>83-534,wt</sup> (red), apo Abl<sup>83-534,E528K</sup> (orange), Abl<sup>83-534,wt</sup>•imatinib (blue), and Abl<sup>83-534,E528K</sup>•imatinib (magenta) showing the increased imatinib-induced core disassembly of the Abl<sup>83-534,E528K</sup> mutant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92324-fig5-v1.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Michaelis-Menten parameters<xref ref-type="table-fn" rid="table1fn1"><sup>*</sup></xref> for the various Abl helix constructs.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Abl<sup>83-534</sup></th><th align="left" valign="bottom">Abl<sup>83-519</sup></th><th align="left" valign="bottom">Abl<sup>83-517</sup></th><th align="left" valign="bottom">Abl<sup>83-515</sup></th><th align="left" valign="bottom">Abl<sup>83-534</sup>•asciminib</th><th align="left" valign="bottom">Abl<sup>83-534,E528K</sup></th></tr></thead><tbody><tr><td align="left" valign="bottom">v<sub>max</sub><xref ref-type="table-fn" rid="table1fn2">†</xref></td><td align="char" char="plusmn" valign="bottom">89.4±6.7</td><td align="char" char="plusmn" valign="bottom">79.5±15.4</td><td align="char" char="plusmn" valign="bottom">56.8±13.3</td><td align="char" char="plusmn" valign="bottom">3.2±0.2</td><td align="char" char="plusmn" valign="bottom">61.9±11.8</td><td align="char" char="plusmn" valign="bottom">201.7±16.0</td></tr><tr><td align="left" valign="bottom">K<sub>M</sub><xref ref-type="table-fn" rid="table1fn3">‡</xref></td><td align="char" char="plusmn" valign="bottom">51.8±8.8</td><td align="char" char="plusmn" valign="bottom">91.4±30.9</td><td align="char" char="plusmn" valign="bottom">74.8±35.7</td><td align="char" char="plusmn" valign="bottom">39.5±9.0</td><td align="char" char="plusmn" valign="bottom">336.7±80.3</td><td align="char" char="plusmn" valign="bottom">71.6±12.3</td></tr><tr><td align="left" valign="bottom">N<xref ref-type="table-fn" rid="table1fn4">§</xref></td><td align="char" char="." valign="bottom">8</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">3</td><td align="char" char="." valign="bottom">2</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>the Michaelis-Menten parameters and their errors were obtained by Monte Carlo fitting using the sample mean and standard error of the mean of the measured kinase activities shown in <xref ref-type="fig" rid="fig5">Figure 5A</xref>.</p></fn><fn id="table1fn2"><label>†</label><p>in nmol P<sub>i</sub> min<sup>–1</sup>μmol<sup>–1</sup>, where P<sub>i</sub> is the transferred phosphate.</p></fn><fn id="table1fn3"><label>‡</label><p>in μM.</p></fn><fn id="table1fn4"><label>§</label><p>total number of activity assay experiments.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-5"><title>Glutamate 528 is a crucial stabilizer for the autoinhibited conformation</title><p>The E528K mutation, located toward the end of helix αI’, has been found in patients with the recently described ABL1 malformation syndrome (<xref ref-type="bibr" rid="bib2">Blakes et al., 2021</xref>). An inspection of the assembled Abl core structure reveals a potential salt bridge between E528 and R479 in the KD C-lobe adjacent to the myristoyl pocket (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). The malignant E528K mutation is expected to disrupt this salt bridge. We speculated that this salt bridge may be a stabilizing element, which restricts the αI’ motion and prevents forces toward the SH2 domain that could lead to core disassembly and higher activity. Albeit we could not study the effect of the αI’-helix length beyond residue 519 due to the instability of the respective truncation mutants, it was possible to express the Abl<sup>83-534,E528K</sup> mutant. Indeed, the chemical shifts of the Abl<sup>83-534,E528K</sup> SH2 and SH3 domains show that this mutant is more disassembled upon imatinib binding than Abl<sup>83-534</sup> (<xref ref-type="fig" rid="fig3">Figures 3B</xref> and <xref ref-type="fig" rid="fig5">5D</xref>). In addition, the kinase activity (v<sub>max</sub>) of the Abl<sup>83-534,E528K</sup> mutant was increased more than two-fold relative to Abl<sup>83-534</sup>, while K<sub>M</sub> remained unaffected (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). Thus, as expected, the disruption of the E528-R479 salt bridge significantly increases both Abl’s enzymatic activity as well as the tendency for Abl core disassembly.</p></sec><sec id="s2-6"><title>Correlation between imatinib-induced Abl core disassembly, apo conformation, and apo kinase activity</title><p>It is striking that for all investigated αI-helix mutants, the kinase activity and the tendency of imatinib to open the assembled core correlate. This can be quantified by comparing the v<sub>max</sub> of these various Abl mutants and the respective principal component 1 (PC1) score of the SH2/SH3 domain chemical shifts in their imatinib-bound forms, which is a measure of the core disassembly (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Indeed, the correlation between v<sub>max</sub> and the PC1 score is highly significant with a Pearson r of 0.89 (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Thus, the imatinib-induced core disassembly and the activating motions required for kinase activity seem to be controlled by a common mechanism, which originates at the αI-helix. A thorough inspection of the PCA results for all SH3SH2KD resonances of the apo αI-helix mutants (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) revealed that its PC2 score also follows the kinase activity. A quantitative correlation revealed a highly significant Pearson r of 0.98 between this PC2 score and v<sub>max</sub> (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Thus, the chemical shift changes captured by the PC2 of the apo αI mutants report structural variations which are related to the changes in the kinase activity. The strongest respective chemical shift changes (according to the PC2 loadings, <xref ref-type="fig" rid="fig6">Figure 6E</xref>) occur at the interface of the SH2 domain (V151, L160, E187, V190, R194, L228) with the KD C-lobe and in the vicinity of the αI N-terminal end (N316, I437, K438). Clearly, as both NMR resonance PC scores (PC1 imatinib-bound forms and PC2 apo forms) correlate to the kinase v<sub>max</sub>, they must also correlate to each other, and a respective high Pearson r of 0.94 is observed (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Taken together, these results show that the truncations and mutations of the αI-helix exert forces from the αI-helix onto the SH2 domain, which modulate both the kinase activity and the imatinib-induced opening of the core.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Correlation between Abl kinase activity, imatinib-induced Abl core disassembly, and αI-helix mutations.</title><p>(<bold>A</bold>) Correlation between the PC1 scores of the SH3SH2 resonances (PCA in <xref ref-type="fig" rid="fig3">Figure 3B</xref>) of all imatinib complexes and the respective kinase activity (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). (<bold>B</bold>) Correlation between the PC2 scores of the SH3SH2KD resonances of all apo forms (PCA in <xref ref-type="fig" rid="fig4">Figure 4D</xref>) and the respective kinase activity (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). The color code for the Abl constructs follows panel A. (<bold>C</bold>) Correlation between the PC1 scores of the SH3SH2 resonances of all imatinib complexes (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) and the PC2 scores of the SH3SH2KD resonances of all apo forms (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). The color code for the Abl constructs follows panel A. (<bold>D</bold>) Residues with absolute PC1 loadings larger than 0.15 from the PCA of the SH3SH2 resonances of all imatinib complexes (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) indicated as red spheres within the structure of the assembled Abl core (PDB 2FO0). (<bold>E</bold>) Residues with absolute PC2 loadings larger than 0.1 from the PCA of the SH3SH2KD resonances of all apo forms (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>) indicated as red spheres within the structure of the assembled Abl core. (<bold>F</bold>) Interface between the αI-helix and the SH2 domain. The bent αI-helix of the assembled core structure is shown in cyan. The straight αI-helix of the isolated Abl kinase domain (PDB 1M52) is shown in magenta stick representation, while residues that clash with the SH2 domain of the assembled Abl core being shown in green stick representation. SH2 residues are displayed as colored spheres. Red: residues with absolute PC2 loadings &gt;0.1 as in panel E, blue: residues with absolute PC2 loadings smaller than 0.1, yellow: residues with unresolved resonances in NMR spectrum.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92324-fig6-v1.tif"/></fig><p>To obtain more insights into these forces we carefully compared the assembled core (myristoylated and in complex with the type I inhibitor PD166326) structure with the bent αI-helix and the isolated Abl kinase domain (in complex with the type I inhibitor PD173955) structure with the straight αI-helix (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). A superposition reveals that steric clashes of the straight αI-helix with the SH2 domain are mostly expected for residues F516, Q517, S520, and I521 residing in the αI–αI’ loop. In the assembled core structure, these residues are within van-der-Waals distance of several SH2 residues, for which no well-resolved resonances could be detected in the NMR spectra (yellow residues in <xref ref-type="fig" rid="fig6">Figure 6F</xref>). However, the latter are in direct contact with the SH2 residues previously identified as having the strongest chemical shift PC2 loadings caused by the mutations of the αI-helix (red residues in <xref ref-type="fig" rid="fig6">Figure 6E and F</xref>). These results establish that the most significant part of the forces from the αI-helix onto the SH2 domain is transmitted from the αI–αI’ loop toward a region on the SH2 surface, which is centered around residue V190.</p></sec><sec id="s2-7"><title>Mechanics of Abl kinase regulation by the αI’-helix</title><p>Based on the current data we can refine our previous mechanical model of Abl regulation (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>), which is based on the assumption that a disassembled regulatory core is necessary for high activity (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Two main mechanical forces drive the opening of the core: F<sub>KD–N,SH3</sub> acts between the KD N-lobe and the SH3 domain and F<sub>αI,SH2</sub> acts between the αI-helix and the SH2 domain.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Mechanical model of Abl allosteric regulation.</title><p>(<bold>A</bold>) Transition between closed (left) and open (right) conformation of Abl’s regulatory core during activation. Arrows indicate mobility of the KD N-lobe and the αI-helix. Clashes between SH3 and KD-N and between SH2 and αI-helix resulting from this mobility are shown by red dots, the related clash-induced forces F<sub>KD-N,SH3</sub> and F<sub>αI,SH2</sub> by red triangles. Color coding: SH3 (green), SH2 (yellow), KD (blue), αI-helix (cyan), A-loop (inactive: magenta, active: green), P-loop (orange), tyrosine substrate (brown), R479-E528 salt bridge (orange). (<bold>B</bold>) Model of imatinib-induced Abl core disassembly. The color code follows panel A. Allo: allosteric inhibitor. (<bold>C</bold>) Detailed model of the interaction between the αI-helix and the SH2 domain for the various investigated Abl αI-helix constructs and inhibitor-bound conformations. The observed, respective Abl activity increases in the direction of the arrow at the bottom. The color code follows panel A.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92324-fig7-v1.tif"/></fig><p>In the absence of ATP site ligands, the KD N-lobe wobbles moderately within the closed regulatory core as evident from conformational exchange observed by NMR (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>). This wobbling exerts a moderate force F<sub>KD–N,SH3</sub> onto the KD N-lobe/SH3 interface. A high flexibility of the αI’-helix has been observed in the absence of myristoyl pocket binders in a KD construct (<xref ref-type="bibr" rid="bib13">Jahnke et al., 2010</xref>). Dynamic motions or static steric clashes of the αI-helix generate a force F<sub>αI,SH2</sub> onto the SH2 domain. The combined effect of F<sub>KD-N,SH3</sub> and F<sub>αI,SH2</sub> in the absence of any ligands lead to an occasional opening of the regulatory core and consequently moderate kinase activity (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p><p>When type II, but not type I inhibitors bind to the ATP pocket, they exert pressure onto the A-loop and P-loop which rotates the entire N-lobe by 5–10° toward the SH3 domain. This rotation is observed in various crystal structures (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>). The rotation increases the force F<sub>KD–N,SH3</sub> and leads to core disassembly. However, when allosteric inhibitors bind to the myristoyl pocket, they reduce the αI’-helix dynamics (<xref ref-type="bibr" rid="bib13">Jahnke et al., 2010</xref>) and thereby the force F<sub>αI,SH2</sub>. This then leads to core reassembly in the presence of type II inhibitors. In the absence of ATP site inhibitors, the reduction of the force F<sub>αI,SH2</sub> by the allosteric inhibitors additionally stabilizes the assembled core and further reduces kinase activity (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p><p>The data of the various truncations and mutations of the αI’-helix provide the following detailed picture of its role in Abl activation (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). In wild-type apo Abl<sup>83-534</sup>, the αI’-helix motion is apparently restricted by the E528-R479 salt bridge. This is evident from the fact that the disruption of the salt bridge in the Abl<sup>83-534,E528K</sup> mutant leads to strongly increased activity (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) and a stronger core disassembly by imatinib (<xref ref-type="fig" rid="fig3">Figures 3B</xref>, <xref ref-type="fig" rid="fig5">5D</xref> and <xref ref-type="fig" rid="fig6">6A</xref>). Both effects can be explained by an increased force F<sub>αI,SH2</sub> acting onto the SH2 domain, which is evident by the increased PC2 score of apo Abl<sup>83-534,E528K‍</sup> (<xref ref-type="fig" rid="fig4">Figures 4D</xref> and <xref ref-type="fig" rid="fig6">6B</xref>). Nevertheless, also the αI-helix of wild-type apo Abl<sup>83-534</sup> exerts a force F<sub>αI,SH2</sub> onto the SH2 domain. The latter is reduced in the presence of certain myristoyl pocket binders such as asciminib, which change the αI-αI’ loop conformation and lock the αI’-helix onto the KD C-lobe. The F<sub>αI,SH2</sub> force of the wild-type αI-helix apparently does not mainly originate from its αI’ part, since the truncation Abl<sup>83-519</sup> has no strong effect. It neither significantly reduces the imatinib-induced core disassembly, nor the apo activity, nor the apo PC2 score, that is the force F<sub>αI,SH2</sub> (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). However, the further truncation Abl<sup>83-515</sup>, which removes the αI-αI’ loop, abolishes the kinase activity almost completely (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>) and strongly decreases the F<sub>αI,SH2</sub> force as well as the imatinib-induced core disassembly (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). This indicates that the αI helix of wild-type Abl mainly exerts the F<sub>αI,SH2</sub> force onto the SH2 domain via the αI-αI’ loop. The αI-αI’ loop is flexible to a certain extent since various conformations are observed in the presence and absence of myristoyl pocket binders. Presumably, the F<sub>αI,SH2</sub> force is exerted by steric clashes of some members from the conformational ensemble of the flexible loop.</p></sec><sec id="s2-8"><title>Conclusion</title><p>The allosteric connection between Abl ATP site and myristate site inhibitor binding has been noted before, albeit specific settings such as construct boundaries and the control of phosphorylation vary in published experiments. Positive and negative binding cooperativity of certain ATP-pocket and allosteric inhibitors has been observed in cellular assays and in vitro (<xref ref-type="bibr" rid="bib14">Kim et al., 2023</xref>; <xref ref-type="bibr" rid="bib30">Zhang et al., 2010</xref>). Furthermore, hydrogen exchange mass spectrometry has indicated changes around the unliganded ATP pocket upon binding of the allosteric inhibitor GNF-5 (<xref ref-type="bibr" rid="bib30">Zhang et al., 2010</xref>). Here, we present a detailed high-resolution explanation of these allosteric effects via a mechanical connection between the kinase domain N- and C-lobes that is mediated by the regulatory SH2 and SH3 domains and involves the αI helix as a crucial element.</p><p>Specifically, we have established a firm correlation between the kinase activity of the Abl regulatory core, the imatinib (type II inhibitor)-induced disassembly of the core, which is caused by a force F<sub>KD–‍N,SH3</sub> between the KD N-lobe and the SH3 domain, and a force F<sub>αI,SH2</sub> exerted by the αI-helix toward the SH2 domain. The F<sub>αI,SH2</sub> force is mainly caused by a clash of the αI-αI’ loop with the SH2 domain. Both the F<sub>KD–N,SH3</sub> and F<sub>αI,SH2</sub> force act on the KD/SH2SH3 interface and may lead to the disassembly of the core, which is in a delicate equilibrium between assembled and disassembled forms. As disassembly is required for kinase activity, the modulation of both forces constitutes a very sensitive regulation mechanism. Allosteric inhibitors such as asciminib and also myristoyl, the natural allosteric pocket binder, pull the αI-αI’ loop away from the SH2 interface, and thereby reduce the F<sub>αI,SH2</sub> force and activity. Notably, all observations described here were obtained under non-phosphorylated conditions, as phosphorylation will lead to additional strong activating effects.</p><p>The presented mechanical force model also explains the malignance of the αI’-helix E528K mutation in the recently described ABL1 malformation syndrome. The native E528 forms a salt bridge with R479 in the KD C-lobe, which stabilizes the inactive, assembled conformation by reducing the conformational space of the αI’-helix, and thereby the F<sub>αI,SH2</sub> force. In contrast, the disruption of the E528-R479 salt bridge by the E528K mutation strongly increases the kinase activity.</p><p>We have used here imatinib binding to the ATP-pocket as an experimental tool to disassemble the Abl regulatory core. Our previous analysis (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>) of the high-resolution Abl transition-state structure (<xref ref-type="bibr" rid="bib16">Levinson et al., 2006</xref>) indicated that due to the extremely tight packing of the catalytic pocket, binding and release of the ATP and tyrosine peptide substrates is only possible if the P-loop and thereby the N-lobe move toward the SH3 domain by about 1–2 Å. This motion is of similar size and direction as the motion of the N-lobe observed in complexes with imatinib and other type II inhibitors (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>). From this we concluded that substrate binding opens the Abl core in a similar way as imatinib. The present NMR and activity data now clearly establish the essential role of the αI-helix both in the imatinib- and substrate-induced opening of the core, thereby further corroborating the similarity of both disassembly processes.</p><p>Notably, the used regulatory core construct Abl<sup>83-534</sup> lacks the myristoylated N-cap. Although we have previously demonstrated that the latter construct is predominantly assembled (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>), the addition of the myristoyl moiety is expected to further stabilize the assembled conformation in a similar way as asciminib. Considering this mechanism, dissociation of myristoyl from the native Abl 1b core may be a first step during activation. However, it should be kept in mind that the Abl 1 a isoform lacks the N-terminal myristoylation, and it is presently unclear whether other moieties bind to the myristoyl pocket of Abl 1 a during cellular processes.</p></sec></sec><sec id="s3" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (Human)</td><td align="left" valign="bottom">Abl</td><td align="left" valign="bottom">Uniprot</td><td align="left" valign="bottom">P00519-2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Escherichia phage lambda</italic>)</td><td align="left" valign="bottom">Lambda phosphatase; LPP</td><td align="left" valign="bottom">Uniprot</td><td align="left" valign="bottom">P03772</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">BL21(DE3)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">CMC0014</td><td align="left" valign="bottom">Chemical competent cells</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Plasmid containing human Abl<sup>83-534</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref><break/>DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1314712110">10.1073/pnas.1314712110</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Plasmid containing Lambda phosphatase</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref><break/>DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/jacs.7b12430">10.1021/jacs.7b12430</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Conjugated poly-histidine antibody</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat.# A7058</td><td align="left" valign="bottom">Mouse monoclonal (1:10000); peroxidase conjugate</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Abltide</td><td align="left" valign="bottom">ProteoGenix</td><td align="left" valign="bottom"/><td align="left" valign="bottom">biotin-GGEAIYAAPFKK</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SAM2 Biotin Capture Membrane</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat.# V2861</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Asciminib; asci</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S8555</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">GNF-5</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S7526</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">AMP-PNP</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat.# 10102547001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Bosutinib; bosu</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S1014</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Axitinib; axit</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S1005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dasatinib; dasa</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S1021</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Danusertib; danu</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S1107</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tozasertib; toza</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S1048</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Staurosporine; staur</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S1421</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PD180970</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat.# PZ0142</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PD166326</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat.# PZ0366</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Rebastinib; reba</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S2634</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ponatinib; pona</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S1490</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nilotinib; nilo</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S1033</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Bafetinib; bafe</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S1369</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Imatinib; ima</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat.# S2475</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">NMRPipe</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib6">Delaglio et al., 1995</xref><break/>DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/bf00197809">10.1007/bf00197809</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">SPARKY</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib15">Lee et al., 2015</xref><break/>DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/bioinformatics/btu830">10.1093/bioinformatics/btu830</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">NumPy</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib12">Harris et al., 2020</xref><break/>DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41586-020-2649-2">10.1038/s41586-020-2649-2</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s3-1"><title>Abl constructs, expression, and purification</title><p>To generate the various Abl αI-helix mutant constructs (Abl<sup>83-513</sup>, Abl<sup>83-514</sup>, Abl<sup>83-515</sup>, Abl<sup>83-516</sup>, Abl<sup>83-‍517</sup>, Abl<sup>83‍-‍518</sup>, Abl<sup>83-519</sup>, and Abl<sup>83-534,E528K</sup>, Abl 1b numbering), stop (TAG) or lysine (AAG) codons were introduced at the respective positions by site-directed QuikChange mutagenesis into the plasmid containing human Abl<sup>83-534</sup>, which was described earlier (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>). For the initial expression and solubility tests, all Abl constructs were co-expressed with lambda phosphatase (LPP; to obtain dephosphorylated Abl) as described earlier (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>) in 25 mL LB medium. After harvesting, cells were resuspended in 1 mL lysis buffer, sonicated, centrifuged and the supernatant collected for western blot analysis with a conjugated poly-histidine antibody (Sigma Aldrich, Cat.No. A7058).</p><p>All Abl constructs used for NMR experiments were co-expressed with LPP in <sup>15</sup>N-labeled M9 minimal medium as described (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>). The cell lysate was cleared by centrifugation at 30,000 × <italic>g</italic>, loaded onto a His-Trap column (GE Healthcare), and eluted by applying a linear imidazole gradient from 20 mM to 200 mM over 30 column volumes. Abl<sup>83-534</sup> was then purified using an ion exchange Q-sepharose HP (GE Healthcare) column equilibrated with 20 mM Tris-HCl, 20 mM NaCl, 2 mM TCEP, 5% glycerol, pH 8.0 (ion exchange buffer). The truncated Abl mutants did not bind to either ion exchange Q- or S-sepharose HP (GE Healthcare) columns in ion exchange buffer. However, using the Q-sepharose HP column helped to remove impurities and the respective Abl constructs were collected in the flow through. In vitro LPP treatment was then applied as described (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>) in cases where the Abl construct was not fully dephosphorylated as indicated by the elution profile and confirmed by electron-spray ionization (ESI) time-of-flight (TOF) mass spectrometry (MS). All Abl constructs were then further purified by size exclusion chromatography as described (<xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>). Final samples were validated by ESI-TOF MS for correct protein mass and absence of contaminations by other proteins.</p></sec><sec id="s3-2"><title>NMR spectroscopy</title><p>As in previous studies (<xref ref-type="bibr" rid="bib25">Skora et al., 2013</xref>; <xref ref-type="bibr" rid="bib26">Sonti et al., 2018</xref>), the isotope-labeled SH3-SH2-KD Abl constructs were concentrated to 25–100 µM in 20 mM Tris·HCl, 100 mM NaCl, 2 mM EDTA, 2 mM TCEP, 0.02% NaN<sub>3</sub>, 95% H<sub>2</sub>O/5% D<sub>2</sub>O, pH 8.0. Ligands pre-dissolved in DMSO (stock concentration 50 mM) were added at a molar ratio of 3:1 (ligand:protein). All NMR experiments were performed at 303 K on a Bruker AVANCE 900-MHz spectrometer equipped with a TCI triple resonance cryo-probe. <sup>1</sup>H-<sup>15</sup>N TROSY experiments were recorded with 224 (<sup>15</sup>N)×1024 (<sup>1</sup>H) complex points and acquisition times of ~40 ms in both dimensions. All NMR data were processed with the NMRpipe software package (<xref ref-type="bibr" rid="bib6">Delaglio et al., 1995</xref>). Spectra were displayed and analyzed with the program SPARKY (<xref ref-type="bibr" rid="bib15">Lee et al., 2015</xref>). The principal component analysis (PCA) of chemical shift variations was carried out using NumPy (<xref ref-type="bibr" rid="bib12">Harris et al., 2020</xref>).</p></sec><sec id="s3-3"><title>PDB structure analysis</title><p>PDB structures were displayed using the PyMOL Molecular Graphics System (Schrödinger, LLC).</p></sec><sec id="s3-4"><title>Activity assays</title><p>A biotinylated form of the optimized Abl substrate Abltide (biotin-GGEAIYAAPFKK, obtained from ProteoGenix, France) was incubated in concentrations ranging from 3.125 µM to 200 µM together with 0.1 ng/μl of the respective Abl construct, 100 μM ATP and 5 μCi γ-<sup>32</sup>P-ATP in 20 μl kinase assay buffer (20 mM Tris-HCl, 5 mM MgCl<sub>2</sub>, 1 mM DTT, 10 μM bovine serum albumin, pH 7.5) for 12 min at room temperature. The reaction was terminated by adding 10 μl 7.5 M guanidine hydrochloride. Eight μl of the terminated reaction mixture were then applied to a streptavidin biotin capture membrane (SAM2, Promega, Cat.# V2861) and further treated following the manufacturer’s recommendations. After a short (~1 min) drying phase, the membrane was washed consecutively 30 s with 2 M NaCl, 3×2 min with 2 M NaCl, 4×2 min with 2 M NaCl +1% H<sub>3</sub>PO<sub>4</sub>, 2×30 s with deionized water, and finally rinsed with ethanol.</p><p>The amount of <sup>32</sup>P incorporated into the Abl substrate was quantified using a liquid scintillation counter (PerkinElmer, model: Tri-Carb4910TR). The Michaelis-Menten parameters and their errors were obtained by Monte Carlo fitting with NumPy (<xref ref-type="bibr" rid="bib12">Harris et al., 2020</xref>) using the sample mean and standard error of the mean of the measured data points.</p></sec></sec></body><back><sec sec-type="additional-information" id="s4"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Software, Formal analysis, Supervision, Funding acquisition, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s5"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-92324-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s6"><title>Data availability</title><p>NMR time domain data, processing scripts, and peak lists for the various Abl αI-helix mutant constructs in apo form and inhibitor complexes have been deposited in the Biological Magnetic Resonance Data Bank (BMRB) under accession codes 52273, 52293, 52296, 52297, 52298, 52300, 52301, 52302, 52305, 52306, 52307, 52310, 52339.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform wild type SH3-SH2-KD (aa 83-534) apo</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52273">52273</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform wild type SH3-SH2-KD (aa 83-534) in complex with asciminib</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52293">52293</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform wild type SH3-SH2-KD (aa 83-519) apo</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52296">52296</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset4"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform wild type SH3-SH2-KD (aa 83-519) in complex with imatinib</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52297">52297</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset5"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform wild type SH3-SH2-KD (aa 83-517) apo</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52298">52298</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset6"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform wild type SH3-SH2-KD (aa 83-517) in complex with imatinib</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52300">52300</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset7"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform wild type SH3-SH2-KD (aa 83-515) apo</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52301">52301</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset8"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform wild type SH3-SH2-KD (aa 83-515) in complex with imatinib</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52302">52302</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset9"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform E528K SH3-SH2-KD (aa 83-534) apo</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52305">52305</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset10"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform E528K SH3-SH2-KD (aa 83-534) in complex with imatinib</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52306">52306</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset11"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform wild type SH3-SH2-KD (aa 83-534) in complex with GNF-5</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52307">52307</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset12"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform wild type SH3-SH2-KD (aa 83-534) in complex with PD166326</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52310">52310</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset13"><person-group person-group-type="author"><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Maier</surname><given-names>A</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Hertel</surname><given-names>I</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Abl 1b isoform wild type SH3-SH2-KD (aa 83-534) in complex with imatinib</data-title><source>Biological Magnetic Resonance Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://bmrb.io/data_library/summary/index.php?bmrbId=52339">52339</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>Drs. Oliver Hantschel, Wolfgang Jahnke, Lukasz Skora, and Layara Akemi Abiko are gratefully acknowledged for helpful discussions. This research has been supported by the Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (grant nos. 31-149927, 31-173089, and 31-201270) and the Krebsliga Schweiz (grant no. KFS-3603-022015).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adrián</surname><given-names>FJ</given-names></name><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>Sim</surname><given-names>T</given-names></name><name><surname>Velentza</surname><given-names>A</given-names></name><name><surname>Sloan</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Hur</surname><given-names>W</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Manley</surname><given-names>P</given-names></name><name><surname>Mestan</surname><given-names>J</given-names></name><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Allosteric inhibitors of Bcr-abl-dependent cell proliferation</article-title><source>Nature Chemical Biology</source><volume>2</volume><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/nchembio760</pub-id><pub-id pub-id-type="pmid">16415863</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blakes</surname><given-names>AJM</given-names></name><name><surname>Gaul</surname><given-names>E</given-names></name><name><surname>Lam</surname><given-names>W</given-names></name><name><surname>Shannon</surname><given-names>N</given-names></name><name><surname>Knapp</surname><given-names>KM</given-names></name><name><surname>Bicknell</surname><given-names>LS</given-names></name><name><surname>Jackson</surname><given-names>MR</given-names></name><name><surname>Wade</surname><given-names>EM</given-names></name><name><surname>Robertson</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>SM</given-names></name><name><surname>Heller</surname><given-names>R</given-names></name><name><surname>Chase</surname><given-names>A</given-names></name><name><surname>Baralle</surname><given-names>D</given-names></name><name><surname>Douglas</surname><given-names>AGL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pathogenic variants causing ABL1 malformation syndrome cluster in a myristoyl-binding pocket and increase tyrosine kinase activity</article-title><source>European Journal of Human Genetics</source><volume>29</volume><fpage>593</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1038/s41431-020-00766-w</pub-id><pub-id pub-id-type="pmid">33223528</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>TP</given-names></name><name><surname>Eide</surname><given-names>CA</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Response and Resistance to BCR-ABL1-Targeted Therapies</article-title><source>Cancer Cell</source><volume>37</volume><fpage>530</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.03.006</pub-id><pub-id pub-id-type="pmid">32289275</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan-Jacob</surname><given-names>SW</given-names></name><name><surname>Fendrich</surname><given-names>G</given-names></name><name><surname>Floersheimer</surname><given-names>A</given-names></name><name><surname>Furet</surname><given-names>P</given-names></name><name><surname>Liebetanz</surname><given-names>J</given-names></name><name><surname>Rummel</surname><given-names>G</given-names></name><name><surname>Rheinberger</surname><given-names>P</given-names></name><name><surname>Centeleghe</surname><given-names>M</given-names></name><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Manley</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>63</volume><fpage>80</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1107/S0907444906047287</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deininger</surname><given-names>MW</given-names></name><name><surname>Goldman</surname><given-names>JM</given-names></name><name><surname>Melo</surname><given-names>JV</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The molecular biology of chronic myeloid leukemia</article-title><source>Blood</source><volume>96</volume><fpage>3343</fpage><lpage>3356</lpage><pub-id pub-id-type="pmid">11071626</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delaglio</surname><given-names>F</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name><name><surname>Vuister</surname><given-names>GW</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Pfeifer</surname><given-names>J</given-names></name><name><surname>Bax</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>NMRPipe: a multidimensional spectral processing system based on UNIX pipes</article-title><source>Journal of Biomolecular NMR</source><volume>6</volume><fpage>277</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1007/BF00197809</pub-id><pub-id pub-id-type="pmid">8520220</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eide</surname><given-names>CA</given-names></name><name><surname>Zabriskie</surname><given-names>MS</given-names></name><name><surname>Savage Stevens</surname><given-names>SL</given-names></name><name><surname>Antelope</surname><given-names>O</given-names></name><name><surname>Vellore</surname><given-names>NA</given-names></name><name><surname>Than</surname><given-names>H</given-names></name><name><surname>Schultz</surname><given-names>AR</given-names></name><name><surname>Clair</surname><given-names>P</given-names></name><name><surname>Bowler</surname><given-names>AD</given-names></name><name><surname>Pomicter</surname><given-names>AD</given-names></name><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Senina</surname><given-names>AV</given-names></name><name><surname>Qiang</surname><given-names>W</given-names></name><name><surname>Kelley</surname><given-names>TW</given-names></name><name><surname>Szankasi</surname><given-names>P</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Tyner</surname><given-names>JW</given-names></name><name><surname>Rea</surname><given-names>D</given-names></name><name><surname>Cayuela</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Tognon</surname><given-names>CE</given-names></name><name><surname>O’Hare</surname><given-names>T</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants</article-title><source>Cancer Cell</source><volume>36</volume><fpage>431</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.08.004</pub-id><pub-id pub-id-type="pmid">31543464</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grzesiek</surname><given-names>S</given-names></name><name><surname>Paladini</surname><given-names>J</given-names></name><name><surname>Habazettl</surname><given-names>J</given-names></name><name><surname>Sonti</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Imatinib disassembles the regulatory core of Abelson kinase by binding to its ATP site and not by binding to its myristoyl pocket</article-title><source>Magnetic Resonance</source><volume>3</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.5194/mr-3-91-2022</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hantschel</surname><given-names>O</given-names></name><name><surname>Nagar</surname><given-names>B</given-names></name><name><surname>Guettler</surname><given-names>S</given-names></name><name><surname>Kretzschmar</surname><given-names>J</given-names></name><name><surname>Dorey</surname><given-names>K</given-names></name><name><surname>Kuriyan</surname><given-names>J</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A myristoyl/phosphotyrosine switch regulates c-Abl</article-title><source>Cell</source><volume>112</volume><fpage>845</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(03)00191-0</pub-id><pub-id pub-id-type="pmid">12654250</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hantschel</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structure, regulation, signaling, and targeting of abl kinases in cancer</article-title><source>Genes &amp; Cancer</source><volume>3</volume><fpage>436</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1177/1947601912458584</pub-id><pub-id pub-id-type="pmid">23226581</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hantschel</surname><given-names>O</given-names></name><name><surname>Grebien</surname><given-names>F</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL</article-title><source>Cancer Research</source><volume>72</volume><fpage>4890</fpage><lpage>4895</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-1276</pub-id><pub-id pub-id-type="pmid">23002203</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>CR</given-names></name><name><surname>Millman</surname><given-names>KJ</given-names></name><name><surname>van der Walt</surname><given-names>SJ</given-names></name><name><surname>Gommers</surname><given-names>R</given-names></name><name><surname>Virtanen</surname><given-names>P</given-names></name><name><surname>Cournapeau</surname><given-names>D</given-names></name><name><surname>Wieser</surname><given-names>E</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Berg</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>NJ</given-names></name><name><surname>Kern</surname><given-names>R</given-names></name><name><surname>Picus</surname><given-names>M</given-names></name><name><surname>Hoyer</surname><given-names>S</given-names></name><name><surname>van Kerkwijk</surname><given-names>MH</given-names></name><name><surname>Brett</surname><given-names>M</given-names></name><name><surname>Haldane</surname><given-names>A</given-names></name><name><surname>Del Río</surname><given-names>JF</given-names></name><name><surname>Wiebe</surname><given-names>M</given-names></name><name><surname>Peterson</surname><given-names>P</given-names></name><name><surname>Gérard-Marchant</surname><given-names>P</given-names></name><name><surname>Sheppard</surname><given-names>K</given-names></name><name><surname>Reddy</surname><given-names>T</given-names></name><name><surname>Weckesser</surname><given-names>W</given-names></name><name><surname>Abbasi</surname><given-names>H</given-names></name><name><surname>Gohlke</surname><given-names>C</given-names></name><name><surname>Oliphant</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Array programming with NumPy</article-title><source>Nature</source><volume>585</volume><fpage>357</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2649-2</pub-id><pub-id pub-id-type="pmid">32939066</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahnke</surname><given-names>W</given-names></name><name><surname>Grotzfeld</surname><given-names>RM</given-names></name><name><surname>Pellé</surname><given-names>X</given-names></name><name><surname>Strauss</surname><given-names>A</given-names></name><name><surname>Fendrich</surname><given-names>G</given-names></name><name><surname>Cowan-Jacob</surname><given-names>SW</given-names></name><name><surname>Cotesta</surname><given-names>S</given-names></name><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Furet</surname><given-names>P</given-names></name><name><surname>Mestan</surname><given-names>J</given-names></name><name><surname>Marzinzik</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay</article-title><source>Journal of the American Chemical Society</source><volume>132</volume><fpage>7043</fpage><lpage>7048</lpage><pub-id pub-id-type="doi">10.1021/ja101837n</pub-id><pub-id pub-id-type="pmid">20450175</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Ludewig</surname><given-names>H</given-names></name><name><surname>Hadzipasic</surname><given-names>A</given-names></name><name><surname>Kutter</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>V</given-names></name><name><surname>Kern</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A biophysical framework for double-drugging kinases</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2304611120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2304611120</pub-id><pub-id pub-id-type="pmid">37590418</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Tonelli</surname><given-names>M</given-names></name><name><surname>Markley</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy</article-title><source>Bioinformatics</source><volume>31</volume><fpage>1325</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu830</pub-id><pub-id pub-id-type="pmid">25505092</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levinson</surname><given-names>NM</given-names></name><name><surname>Kuchment</surname><given-names>O</given-names></name><name><surname>Shen</surname><given-names>K</given-names></name><name><surname>Young</surname><given-names>MA</given-names></name><name><surname>Koldobskiy</surname><given-names>M</given-names></name><name><surname>Karplus</surname><given-names>M</given-names></name><name><surname>Cole</surname><given-names>PA</given-names></name><name><surname>Kuriyan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A Src-like inactive conformation in the abl tyrosine kinase domain</article-title><source>PLOS Biology</source><volume>4</volume><elocation-id>e144</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0040144</pub-id><pub-id pub-id-type="pmid">16640460</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagar</surname><given-names>B</given-names></name><name><surname>Bornmann</surname><given-names>WG</given-names></name><name><surname>Pellicena</surname><given-names>P</given-names></name><name><surname>Schindler</surname><given-names>T</given-names></name><name><surname>Veach</surname><given-names>DR</given-names></name><name><surname>Miller</surname><given-names>WT</given-names></name><name><surname>Clarkson</surname><given-names>B</given-names></name><name><surname>Kuriyan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</article-title><source>Cancer Research</source><volume>62</volume><fpage>4236</fpage><lpage>4243</lpage><pub-id pub-id-type="pmid">12154025</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagar</surname><given-names>B</given-names></name><name><surname>Hantschel</surname><given-names>O</given-names></name><name><surname>Young</surname><given-names>MA</given-names></name><name><surname>Scheffzek</surname><given-names>K</given-names></name><name><surname>Veach</surname><given-names>D</given-names></name><name><surname>Bornmann</surname><given-names>W</given-names></name><name><surname>Clarkson</surname><given-names>B</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name><name><surname>Kuriyan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Structural basis for the autoinhibition of c-Abl tyrosine kinase</article-title><source>Cell</source><volume>112</volume><fpage>859</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(03)00194-6</pub-id><pub-id pub-id-type="pmid">12654251</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagar</surname><given-names>B</given-names></name><name><surname>Hantschel</surname><given-names>O</given-names></name><name><surname>Seeliger</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>JM</given-names></name><name><surname>Weis</surname><given-names>WI</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name><name><surname>Kuriyan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase</article-title><source>Molecular Cell</source><volume>21</volume><fpage>787</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2006.01.035</pub-id><pub-id pub-id-type="pmid">16543148</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Hare</surname><given-names>T</given-names></name><name><surname>Shakespeare</surname><given-names>WC</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Eide</surname><given-names>CA</given-names></name><name><surname>Rivera</surname><given-names>VM</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Adrian</surname><given-names>LT</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>WS</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Metcalf</surname><given-names>CA</given-names></name><name><surname>Tyner</surname><given-names>JW</given-names></name><name><surname>Loriaux</surname><given-names>MM</given-names></name><name><surname>Corbin</surname><given-names>AS</given-names></name><name><surname>Wardwell</surname><given-names>S</given-names></name><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Keats</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sundaramoorthi</surname><given-names>R</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Snodgrass</surname><given-names>J</given-names></name><name><surname>Commodore</surname><given-names>L</given-names></name><name><surname>Sawyer</surname><given-names>TK</given-names></name><name><surname>Dalgarno</surname><given-names>DC</given-names></name><name><surname>Deininger</surname><given-names>MWN</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Clackson</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</article-title><source>Cancer Cell</source><volume>16</volume><fpage>401</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.09.028</pub-id><pub-id pub-id-type="pmid">19878872</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pendergast</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The Abl family kinases: mechanisms of regulation and signaling</article-title><source>Advances in Cancer Research</source><volume>85</volume><fpage>51</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/s0065-230x(02)85003-5</pub-id><pub-id pub-id-type="pmid">12374288</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Réa</surname><given-names>D</given-names></name><name><surname>Mauro</surname><given-names>MJ</given-names></name><name><surname>Boquimpani</surname><given-names>C</given-names></name><name><surname>Minami</surname><given-names>Y</given-names></name><name><surname>Lomaia</surname><given-names>E</given-names></name><name><surname>Voloshin</surname><given-names>S</given-names></name><name><surname>Turkina</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>D-W</given-names></name><name><surname>Apperley</surname><given-names>JF</given-names></name><name><surname>Abdo</surname><given-names>A</given-names></name><name><surname>Fogliatto</surname><given-names>LM</given-names></name><name><surname>Kim</surname><given-names>DDH</given-names></name><name><surname>le Coutre</surname><given-names>P</given-names></name><name><surname>Saussele</surname><given-names>S</given-names></name><name><surname>Annunziata</surname><given-names>M</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Chaudhri</surname><given-names>N</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Chee</surname><given-names>L</given-names></name><name><surname>García-Gutiérrez</surname><given-names>V</given-names></name><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Aimone</surname><given-names>P</given-names></name><name><surname>Allepuz</surname><given-names>A</given-names></name><name><surname>Quenet</surname><given-names>S</given-names></name><name><surname>Bédoucha</surname><given-names>V</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A phase 3, open-label, randomized study of asciminib, A STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs</article-title><source>Blood</source><volume>138</volume><fpage>2031</fpage><lpage>2041</lpage><pub-id pub-id-type="doi">10.1182/blood.2020009984</pub-id><pub-id pub-id-type="pmid">34407542</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1973">1973</year><article-title>Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining</article-title><source>Nature</source><volume>243</volume><fpage>290</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/243290a0</pub-id><pub-id pub-id-type="pmid">4126434</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>NP</given-names></name><name><surname>Skaggs</surname><given-names>BJ</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Nicoll</surname><given-names>JM</given-names></name><name><surname>Paquette</surname><given-names>RL</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency</article-title><source>The Journal of Clinical Investigation</source><volume>117</volume><fpage>2562</fpage><lpage>2569</lpage><pub-id pub-id-type="doi">10.1172/JCI30890</pub-id><pub-id pub-id-type="pmid">17710227</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skora</surname><given-names>L</given-names></name><name><surname>Mestan</surname><given-names>J</given-names></name><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Jahnke</surname><given-names>W</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors</article-title><source>PNAS</source><volume>110</volume><fpage>E4437</fpage><lpage>E4445</lpage><pub-id pub-id-type="doi">10.1073/pnas.1314712110</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonti</surname><given-names>R</given-names></name><name><surname>Hertel-Hering</surname><given-names>I</given-names></name><name><surname>Lamontanara</surname><given-names>AJ</given-names></name><name><surname>Hantschel</surname><given-names>O</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ATP site ligands determine the assembly State of the Abelson Kinase Regulatory Core via the activation loop conformation</article-title><source>Journal of the American Chemical Society</source><volume>140</volume><fpage>1863</fpage><lpage>1869</lpage><pub-id pub-id-type="doi">10.1021/jacs.7b12430</pub-id><pub-id pub-id-type="pmid">29319304</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Etten</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Cycling, stressed-out and nervous: cellular functions of c-Abl</article-title><source>Trends in Cell Biology</source><volume>9</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/s0962-8924(99)01549-4</pub-id><pub-id pub-id-type="pmid">10322452</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Charng</surname><given-names>W-L</given-names></name><name><surname>Chen</surname><given-names>C-A</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Al Shamsi</surname><given-names>A</given-names></name><name><surname>Al-Gazali</surname><given-names>L</given-names></name><name><surname>McGuire</surname><given-names>M</given-names></name><name><surname>Mew</surname><given-names>NA</given-names></name><name><surname>Arnold</surname><given-names>GL</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Muzny</surname><given-names>DM</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Eng</surname><given-names>CM</given-names></name><name><surname>Walkiewicz</surname><given-names>M</given-names></name><name><surname>Xia</surname><given-names>F</given-names></name><name><surname>Plon</surname><given-names>SE</given-names></name><name><surname>Lupski</surname><given-names>JR</given-names></name><name><surname>Schaaf</surname><given-names>CP</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Germline mutations in ABL1 cause an autosomal dominant syndrome characterized by congenital heart defects and skeletal malformations</article-title><source>Nature Genetics</source><volume>49</volume><fpage>613</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1038/ng.3815</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wylie</surname><given-names>AA</given-names></name><name><surname>Schoepfer</surname><given-names>J</given-names></name><name><surname>Jahnke</surname><given-names>W</given-names></name><name><surname>Cowan-Jacob</surname><given-names>SW</given-names></name><name><surname>Loo</surname><given-names>A</given-names></name><name><surname>Furet</surname><given-names>P</given-names></name><name><surname>Marzinzik</surname><given-names>AL</given-names></name><name><surname>Pelle</surname><given-names>X</given-names></name><name><surname>Donovan</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Buonamici</surname><given-names>S</given-names></name><name><surname>Hassan</surname><given-names>AQ</given-names></name><name><surname>Lombardo</surname><given-names>F</given-names></name><name><surname>Iyer</surname><given-names>V</given-names></name><name><surname>Palmer</surname><given-names>M</given-names></name><name><surname>Berellini</surname><given-names>G</given-names></name><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Thohan</surname><given-names>S</given-names></name><name><surname>Bitter</surname><given-names>H</given-names></name><name><surname>Branford</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>DM</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Petruzzelli</surname><given-names>L</given-names></name><name><surname>Vanasse</surname><given-names>KG</given-names></name><name><surname>Warmuth</surname><given-names>M</given-names></name><name><surname>Hofmann</surname><given-names>F</given-names></name><name><surname>Keen</surname><given-names>NJ</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1</article-title><source>Nature</source><volume>543</volume><fpage>733</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1038/nature21702</pub-id><pub-id pub-id-type="pmid">28329763</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Adrián</surname><given-names>FJ</given-names></name><name><surname>Jahnke</surname><given-names>W</given-names></name><name><surname>Cowan-Jacob</surname><given-names>SW</given-names></name><name><surname>Li</surname><given-names>AG</given-names></name><name><surname>Iacob</surname><given-names>RE</given-names></name><name><surname>Sim</surname><given-names>T</given-names></name><name><surname>Powers</surname><given-names>J</given-names></name><name><surname>Dierks</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>G-R</given-names></name><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>Okram</surname><given-names>B</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Wojciechowski</surname><given-names>A</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Fendrich</surname><given-names>G</given-names></name><name><surname>Strauss</surname><given-names>A</given-names></name><name><surname>Vajpai</surname><given-names>N</given-names></name><name><surname>Grzesiek</surname><given-names>S</given-names></name><name><surname>Tuntland</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Bursulaya</surname><given-names>B</given-names></name><name><surname>Azam</surname><given-names>M</given-names></name><name><surname>Manley</surname><given-names>PW</given-names></name><name><surname>Engen</surname><given-names>JR</given-names></name><name><surname>Daley</surname><given-names>GQ</given-names></name><name><surname>Warmuth</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors</article-title><source>Nature</source><volume>463</volume><fpage>501</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/nature08675</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92324.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role specific-use="editor">Reviewing Editor</role></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This manuscript describes an <bold>important</bold> NMR investigation of allosteric interactions within Abl kinase. The authors identify helix I as a major element that couples the Abl active site with the myristate-binding pocket. The <bold>convincing</bold> findings have implications for understanding Abl kinase activation and how to target Abl kinase in diseases.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92324.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors identify a mechanical model of activation of Abelson kinase involving the modification of stability of an alpha helix by mutations and different classes of inhibitors. They use NMR chemical shifts of mutant sequences of the alpha helix in a model of Abelson kinase including the regulatory and kinase domains.</p><p>Strengths:</p><p>The mechanism of inhibition of this important drug target is highly complex involving multiple domains' interactions, While crystal structures can establish end states well, the details of more dynamic interactions among the components can be assessed by NMR studies, The authors previously established {Sonti, 2018, PMID29319304} that different inhibitors and assembled states result from changes of stabilisation of the assembly involving the kinase and the SH3 domain. This is extended here to illuminate the role of the kinase C terminal alpha helic I' to the domains' interface, expanding the previous identification of this area of the protein as key to agonist/antagonist action at the allosteric myristlylation binding site.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92324.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In this paper, Paladini and colleagues investigate the concerted motions within the Abl kinase that control its conformational transition between the active (disassembled) and inactive (assembled state). This work follows their previously published findings that binding of the type II inhibitor, imatinib to the active site of Abl, leads to kinase core disassembly via the force imposed by the P-loop and other regions of the N-lobe on the SH3 domain. Interestingly, imatinib-induced disassembly is prevented when an allosteric inhibitor, asciminib, binds to the myristate-binding pocket. Key to asciminib and myristate binding are motions of helix I, located in the C-lobe, and thus, helix I is hypothesized to be the sensor of the imatinib-induced changes. Specifically, bending of helix I upon engagement of myristate or asciminib was postulated to be important for re-assembly of the autoinhibited Abl core, and thus, reducing the &quot;force&quot; with which kinase N-lobe pushes against the SH2 domain upon binding imatinib.</p><p>The authors use NMR to measure conformational transitions in the several 15N-labeled Abl kinase constructs that display different degrees of helix I truncations. This analysis is slightly limited by the instability of the constructs that carry truncations beyond the helix I &quot;bend&quot;. Nevertheless, it is sufficient to establish that truncation of helix I that removes its fragment, which is in contact with myristate or asciminib ligands, results in loss of the ability of helix I to impose &quot;force&quot; on the SH2 domain that results in kinase core disassembly, even in the presence of imatinib binding. In the absence of this force, the allosteric coupling between the helix I/SH2 and KD/SH3 interfaces is compromised. Principle component analysis is used to analyze the NMR data, and it is very clear and convincing.</p><p>A compelling evidence in support of the proposed allosteric mechanism comes from the analysis of the E528K disease mutation, identified in the Abl1 malformation syndrome. The authors show that this mutant, poised to break a salt bridge formed between E528 in the C-terminal portion of helix I and R479 on the kinase domain, increases helix I outward motions resulting in core disassembly and higher Abl kinase activity. Together, these results reinforce that helix I motions are central to the mechanism of kinase activation via core disassembly.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92324.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Paladini</surname><given-names>Johannes</given-names></name><role specific-use="author">Author</role></contrib><contrib contrib-type="author"><name><surname>Maier</surname><given-names>Annalena</given-names></name><role specific-use="author">Author</role></contrib><contrib contrib-type="author"><name><surname>Habazettl</surname><given-names>Judith Maria</given-names></name><role specific-use="author">Author</role></contrib><contrib contrib-type="author"><name><surname>Hertel</surname><given-names>Ines</given-names></name><role specific-use="author">Author</role></contrib><contrib contrib-type="author"><name><surname>Sonti</surname><given-names>Rajesh</given-names></name><role specific-use="author">Author</role></contrib><contrib contrib-type="author"><name><surname>Grzesiek</surname><given-names>Stephan</given-names></name><role specific-use="author">Author</role></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>This is significant work, and you should certainly make the best case you can on the weaknesses discussed.</p></disp-quote><p>We thank reviewer for this positive comment on the significance of our work. The referee indicates as weaknesses (i) that the force involving the bent or straight αI-helix is not readily apparent, (ii) the residue types were not varied in the helix mutations, and (iii) that the chemical shift perturbations are indirect observations.</p><p>We think we have tried to address a large part of these questions by being very careful in our analysis and by the discussion in the manuscript. The following remarks may help to clarify this further:</p><p>(i) The force emanating from the helix is e.g. visualized in the PC2 loadings in Figure 6E of the PCA carried on all observed SH3-SH2-KD resonances for all apo forms of the helix mutants. The SH2 residues identified by these loadings are in direct vicinity to the αI-helix. The respective PC2 scores correlate to 98% with the vmax of the catalytic reaction and to 94 % with the PC1 scores found for imatinib-induced opening. Importantly, the structure of the KD with the straight αI-helix indicates that mostly residues F516, Q517, S520, and I521 would clash with the SH2 domain in a closed core (Figure 6F). Thus, the expected clashes are in direct vicinity of the SH2 residues identified by the PC2 loadings as correlated to vmax and imatinib-induced opening. These data are completely orthogonal and show that most of the force is coming from residues F516, Q517, S520, and I521 in the αI-αI’ turn.</p><p>(ii) We agree that we mainly used truncations of the αI-helix to study its involvement in activation. Point (i) makes it clear that a larger part of the αI-helix effects is caused by steric clashes of the residues in the αI-αI’ turn. In the latter region, we don’t expect strong amino acid type-specific effects besides excluded volume. Due to expression problems, we could not vary the helix length between residues 519 and 534. However, in this region we introduced the amino acid type mutation E528K. The latter showed a clear specific effect. Further amino acid type-specific effects may be possible in this region. However, we expect that the identified electrostatic E528-R479 interaction is one of the most important interactions in this region.</p><p>(iii) We agree that chemical shift changes of individual resonances are often hard to interpret. However, we want to stress that our conclusions are all drawn from principal component analyses, which in all cases had as input well over 100 if not over 200 1H-15H resonances. The first two principal components of these analyses are robust averages over many residues, which reveal general correlated structural trends.</p><disp-quote content-type="editor-comment"><p>We assume that chemical shift deposition etc will be pursued.</p></disp-quote><p>We are currently depositing a larger collection of our Abl data to the “Biological Magnetic Resonance Data Bank (BMRB)”, which includes the NMR chemical shift data of the present work. A ‘collection’ will be a new feature of the BMRB, and we are in discussion with their staff. We will provide the accession codes as soon as possible (probably within the next month) to be included into the final version of the manuscript. We have amended the Data Availability Section accordingly.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>1. The overall discussion of the implications of the described allostery on kinase activation is provided through lenses of imatinib binding, which is used as an experimental trigger to disassemble the autoinhibited core. Can the authors elaborate in the Discussion on what event would play this role in the kinase catalytic cycle, communicating to helix I? Would dissociation of the myristate from the active site be hypothesized to be the first step in kinase activation? While I understand that certainty may be challenging to attain, it would be good to introduce some ideas into the Discussion.</p></disp-quote><p>We appreciate the reviewer’s suggestions for the discussion and added the following text to the Conclusion section:</p><p>&quot;We have used here imatinib binding to the ATP-pocket as an experimental tool to disassemble the Abl regulatory core. Our previous analysis (Sonti et al., 2018) of the high-resolution Abl transition-state structure (Levinson et al., 2006) indicated that due to the extremely tight packing of the catalytic pocket, binding and release of the ATP and tyrosine peptide substrates is only possible if the P-loop and thereby the N-lobe move towards the SH3 domain by about 1–2 Å. This motion is of similar size and direction as the motion of the N-lobe observed in complexes with imatinib and other type II inhibitors (Sonti et al., 2018). From this we concluded that substrate binding opens the Abl core in a similar way as imatinib. The present NMR and activity data now clearly establish the essential role of the αI-helix both in the imatinib- and substrate-induced opening of the core, thereby further corroborating the similarity of both disassembly processes.</p><p>Notably, the used regulatory core construct Abl83-534 lacks the myristoylated N-cap. Although we have previously demonstrated that the latter construct is predominantly assembled (Skora et al., 2013), the addition of the myristoyl moiety is expected to further stabilize the assembled conformation in a similar way as asciminib.</p><p>Considering this mechanism, dissociation of myristoyl from the native Abl 1b core may be a first step during activation. However, it should be kept in mind that the Abl 1a isoform lacks the N-terminal myristoylation, and it is presently unclear whether other moieties bind to the myristoyl pocket of Abl 1a during cellular processes.&quot;</p><disp-quote content-type="editor-comment"><p>1. Can the authors comment more on the differentiation between assembled conformations induced by type I inhibitor binding vs apo forms (or AMP-PNP and allosteric inhibitor) reported in Figure 3B? The differences are clearly identified by PCA but not sufficiently discussed.</p></disp-quote><p>As indicated in the text, we think two structural effects are intermingled within PC2. Due to this admixture, it is hard to draw strong conclusions and we don’t want to expand on this too much. We have slightly modified the respective paragraph (p.7) as follows:</p><p>&quot;As the affected residues react differently to perturbations by type I inhibitors and truncation of the αI’-helix (Figure 3A, right), we attribute this behavior to two effects intermixed into the PC2 detection: (i) a minor rearrangement of the SH3/KD N-lobe interface caused by filling of the ATP pocket with type I inhibitors, which in contrast to the stronger N-lobe motion induced by type II inhibitors does not yet lead to core disassembly and (ii) a small rearrangement of the SH2/KD C-lobe interface caused by shortening and mutations of the αI-helix.&quot;</p><disp-quote content-type="editor-comment"><p>1. The allosteric connection between active site inhibitor binding and the myristate/allosteric inhibitor binding has been observed in the past and noted before, in papers such as Zhang et al, Nature 2010. While the authors reference this paper, they do not acknowledge its specific findings or engage in a broader discussion of how their conclusions relate to this work.</p></disp-quote><p>We have modified the beginning of the Conclusion section:</p><p>&quot;The allosteric connection between Abl ATP site and myristate site inhibitor binding has been noted before, albeit specific settings such as construct boundaries and the control of phosphorylation vary in published experiments. Positive and negative binding cooperativity of certain ATP-pocket and allosteric inhibitors has been observed in cellular assays and in vitro (Kim et al., 2023; Zhang et al., 2010). Furthermore, hydrogen exchange mass spectrometry has indicated changes around the unliganded ATP pocket upon binding of the allosteric inhibitor GNF-5 (Zhang et al., 2010). Here, we present a detailed high-resolution explanation of these allosteric effects via a mechanical connection between the kinase domain N- and C-lobes that is mediated by the regulatory SH2 and SH3 domains and involves the αI helix as a crucial element.</p><p>Specifically, we have established a firm correlation between the kinase activity of the Abl regulatory core, the imatinib (type II inhibitor)-induced disassembly of the core, which is caused by a force FKD–N,SH3 between the KD N-lobe and the SH3 domain, and a force FαI,SH2 exerted by the αI-helix towards the SH2 domain. The FαI,SH2 force is mainly caused by a clash of the αI-αI’ loop with the SH2 domain. Both the FKD–N,SH3 and FαI,SH2 force act on the KD/SH2SH3 interface and may lead to the disassembly of the core, which is in a delicate equilibrium between assembled and disassembled forms. As disassembly is required for kinase activity, the modulation of both forces constitutes a very sensitive regulation mechanism. Allosteric inhibitors such as asciminib and also myristoyl, the natural allosteric pocket binder, pull the αI-αI’ loop away from the SH2 interface, and thereby reduce the FαI,SH2 force and activity. Notably, all observations described here were obtained under nonphosphorylated conditions, as phosphorylation will lead to additional strong activating effects.&quot;</p><disp-quote content-type="editor-comment"><p>1. Figure 6 could do a better job of providing an illustration of steric clashes.</p></disp-quote><p>We have revised Figure 6, panel F, in order to better illustrate the steric clashes, and modified the legend accordingly.</p><disp-quote content-type="editor-comment"><p>1. There is a typo in line 5 from the top on page 11 (dash missing from &quot;83534&quot; superscript).</p></disp-quote><p>Thank you. This was fixed.</p></body></sub-article></article>